SCHEMBL33532200

SCHEMBL33532200

COc1cc(-c2cn(C)c(=O)c(C)c2C)cc(OC)c1C(=O)N(C)C1CCNCC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD9 Q9H8M2 11/20 0.52
BRD4 O60885 9/20 0.52
BRD7 Q9NPI1 6/20 0.52
BRD2 P25440 4/20 0.52
PLAT P00750 2/20 0.38
SIK1 P57059 1/20 0.36
SIK2 Q9H0K1 1/20 0.36
SIK3 Q9Y2K2 1/20 0.36
TGFBR1 P36897 2/20 0.36
ACVR1 Q04771 2/20 0.36
TAF1 P21675 2/20 0.34
CECR2 Q9BXF3 2/20 0.34
TLR9 Q9NR96 1/20 0.34
TLR8 Q9NR97 1/20 0.34
TLR7 Q9NYK1 1/20 0.34
BRPF1 P55201 1/20 0.34
BPTF Q12830 1/20 0.34
TAF1L Q8IZX4 1/20 0.34
CREBBP Q92793 1/20 0.34
BAZ2B Q9UIF8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL33532167 0.81 BRD9 (0.67) BRD9BRD4BRD7BRD2TGFBR1
SCHEMBL33530676 0.78 BRD4 (0.51) BRD9BRD4BRD7BRD2TGFBR1
SCHEMBL23783319 0.75 BRD4 (0.61) BRD9BRD4BRD7BRD2TGFBR1
SCHEMBL26134264 0.74 BRD4 (0.60) BRD9BRD4BRD7BRD2TGFBR1
SCHEMBL23134701 0.72 BRD4 (0.70) BRD9BRD4BRD7BRD2TGFBR1
SCHEMBL30297130 0.72 BRD9 (0.54) BRD9BRD4BRD7BRD2TGFBR1
SCHEMBL23122765 0.72 BRD9 (0.52) BRD9BRD4BRD7BRD2TGFBR1
Hydrochloric Acid SCHEMBL23121899 0.71 BRD9 (0.51) BRD9BRD4BRD7BRD2TGFBR1
SCHEMBL23783303 0.71 BRD4 (0.55) BRD9BRD4BRD7BRD2TGFBR1
SCHEMBL30297134 0.71 BRD9 (0.53) BRD9BRD4BRD7BRD2TGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260092061-A1 COMPOUNDS FOR TARGETED PROTEIN DEGRADATION AMPHISTA THERAPEUTICS LTD (GB) 2026-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260092061-A1 COMPOUNDS FOR TARGETED PROTEIN DEGRADATION BCL9L, RBBP9, BRD9 BRD9 3/4885BRD4 161/4885BRD7 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.